Study Summary
Establishing real-world data of Chinese patients with CD19-positive relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) treated with Puzolcabtagene Autoleucel Injection to evaluate its effectiveness.
Interested in this trial?
Submit an InquiryInterventions
Puzolcabtagene Autoleucel InjectionDRUG
An autologous T-cell suspension expressing the CD19 chimeric antigen receptor（CD19 CAR-T)
Study Locations
No locations listed.